Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon for Post-bariatric Hypoglycemia
NCT04824872Phase 2Withdrawn
- Sponsor
- Zealand Pharma
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of dasiglucagon in post-bariatric hypoglycemia (PBH), sponsored by Zealand Pharma. Planned start Feb 2023; status: withdrawn.
02
Drugs
dasiglucagon
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NCT04824872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04824872.